Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia

Full text
Author(s):
Quintino de Oliveira, Bruno [1] ; Catto, Luiz F. B. [1] ; Santana, Barbara A. A. [1] ; Tellechea, M. Florencia [1] ; Scheucher, Priscila S. [1] ; Scheinberg, Phillip [2] ; Calado, Rodrigo T. [1]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Dept Med Imaging Haematol & Clin Oncol, Ribeirao Preto Sch Med, Ribeirao Preto - Brazil
[2] Hosp Beneficencia Portuguesa, Div Haematol, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: British Journal of Haematology; v. 193, n. 2 NOV 2020.
Web of Science Citations: 1
Abstract

Eltrombopag has been added to first-line treatment of immune aplastic anaemia (AA), resulting in higher responses. We analysed marrow samples of AA patients who responded to immunosuppressive therapy (IST) alone or in combination with eltrombopag for the composition of the haematopoietic stem and progenitor cell (HSPC) compartment. The number of CD34(+) cells and multipotent progenitors was higher in patients treated with eltrombopag (P P < 0 center dot 05; respectively), but not the number of stem cells. No aberrant phenotype was observed. These results indicate that eltrombopag augments CD34(+) cells in vivo and preferentially expands multipotent progenitors, but not stem cells. (AU)

FAPESP's process: 18/25178-0 - Effect of eltrombopag on the expansion of hematopoietic stem and progenitor cells in the treatment of aplastic anemia
Grantee:Bruno Quintino de Oliveira
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC